Company research / CVKD
Cadrenal Therapeutics, Inc. (CVKD)
- Sector Manufacturing
- Incorporated DE
- Fiscal year ends around Dec 31
Key ratios (year ended 2025-12-31)
-483.3%
Return on year-end equity
Beyond the statements
Follow the company.
Explore new filings, reported insider transactions and company relationships.
Annual financials
| Period ended | TTM to 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2008-03-31 |
|---|---|---|---|---|---|---|
| Cost of Revenue | n/a | n/a | n/a | $220.1K | n/a | $220.1K |
| R&D Expense | $2.83M | $4.10M | $4.21M | $4.08M | n/a | n/a |
| Operating Income | -$11.65M | -$13.46M | -$10.96M | -$7.63M | n/a | n/a |
| Net Income | -$11.54M | -$13.24M | -$10.65M | -$8.36M | n/a | n/a |
| EPS (Diluted) | n/a | -$6.64 | -$8.73 | -$9.29 | n/a | n/a |
| Total Assets | $5.59M | $4.33M | $10.12M | $8.52M | $778.2K | n/a |
| Total Liabilities | $1.50M | $1.59M | $2.68M | $826.9K | $6.33M | n/a |
| Shareholders' Equity | $4.09M | $2.74M | $7.44M | $7.69M | -$5.55M | n/a |
| Cash & Equivalents | $2.39M | $4.01M | $10.02M | $8.40M | $32.6K | n/a |
| Operating Cash Flow | -$10.16M | -$12.60M | -$7.36M | -$3.53M | n/a | n/a |
| Capital Expenditures | n/a | $5.1K | $6.5K | $3.3K | n/a | n/a |
| Free Cash Flow | n/a | -$12.61M | -$7.36M | -$3.53M | n/a | n/a |
| Shares Outstanding | 3.10M | 2.34M | 1.78M | 868.2K | 8.19M | n/a |
| Dividends Per Share | n/a | $16.50 | $16.50 | n/a | n/a | n/a |
| Weighted Average Diluted Shares | n/a | 1.99M | 1.22M | 899.5K | n/a | n/a |
| EPS (Basic) | n/a | -$6.64 | -$8.73 | -$9.29 | n/a | n/a |